As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
Announcement: COVID-19 impact on peer review
Wellington et al. 2020
Featured Research: Cerebrovascular amyloid Angiopathy in bioengineered vessels is reduced by high-density lipoprotein particles enriched in Apolipoprotein E
Jerome Robert, …, and Cheryl L. Wellington
Sharon et al. 2020
Featured Research: A role for α-Synuclein in axon growth and its implications in corticostriatal glutamatergic plasticity in Parkinson’s disease
Meir Schechter, …, and Ronit Sharon
Dawson et al. 2020
Featured Review: PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson’s disease
Preston Ge, Valina L. Dawson and Ted M. Dawson
Hijaz and Volpicelli-Daley 2020
Featured Review: Initiation and propagation of α-synuclein aggregation in the nervous system
Baraa A. Hijaz and Laura A. Volpicelli-Daley
Articles
-
-
Flow-cytometric microglial sorting coupled with quantitative proteomics identifies moesin as a highly-abundant microglial protein with relevance to Alzheimer’s disease
-
α-Synucleinopathy associated c-Abl activation causes p53-dependent autophagy impairment
-
NLRP12 collaborates with NLRP3 and NLRC4 to promote pyroptosis inducing ganglion cell death of acute glaucoma
-
Dynamic changes of CSF sTREM2 in preclinical Alzheimer’s disease: the CABLE study
-
Exosomal cell-to-cell transmission of alpha synuclein oligomers
-
Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1polymorphisms
-
Drosophila melanogaster as a model organism for Alzheimer’s disease
-
The SH-SY5Y cell line in Parkinson’s disease research: a systematic review
-
The Alzheimer's disease β-secretase enzyme, BACE1
Editor highlights
ICMN2020 Conference
It is with regret we announce the cancellation of the 6th International Conference on Molecular Neurodegeneration, due to the unstable situation and travel restrictions surrounding the novel Coronavirus.
Please see the ICMN website for further details.
Parkinson's disease - a series of reviews
Molecular Neurodegeneration presents a new thematic series, collating reviews on recent advances in Parkinson's Disease research.
Guest Edited by Mark Cookson and Ted Dawson, reviews will continue to publish throughout 2020. The collection can be read here.
About Us
The leading open access journal in the field of neurosciences, Molecular Neurodegeneration encompasses all aspects of neurodegeneration research at the molecular and cellular levels.
Editors-in-Chief:
- Guojun Bu, Mayo Clinic, USA
- Huaxi Xu, Sanford Burnham Prebys Medical Discovery Institute, USA
Advertisement
Follow
Editors-in-Chief
Guojun Bu, Mayo Clinic, USA
Huaxi Xu, Sanford Burnham Prebys Medical Discovery Institute, USA
Annual Journal Metrics
-
Speed
43 days to first decision for reviewed manuscripts only
20 days to first decision for all manuscripts
121 days from submission to acceptance
23 days from acceptance to publication
Citation Impact
8.274 - 2-year Impact Factor
8.102 - 5-year Impact Factor
1.436 - Source Normalized Impact per Paper (SNIP)
3.988 - SCImago Journal Rank (SJR)
Usage
568,061 downloads
570 Altmetric mentions
Advertisement
